Posts Tagged ‘DNA’

Asbestos alternative also damages DNA, study finds

14 Jul 2017 by under News

800px How joint 100x100 Asbestos alternative also damages DNA, study findsA new Chinese study suggests an asbestos alternative can cause the same type damage as the carcinogen it was meant to replace, potentially increasing health concerns for those who used a product they believed was safe. (more…)


Compound in Asian spice linked to mesothelioma cell death

23 Feb 2017 by under News

Kurkumina 100x100 Compound in Asian spice linked to mesothelioma cell deathA yellow spice that gives several Asian cuisines color and flavor has also been used for traditional medicinal purposes in the region for decades. Recently, the compound that gives turmeric its yellow color and powerful flavor, curcumin, is the subject of numerous malignant (MM) studies. (more…)


New drug could reduce DNA modifications, improve mesothelioma patient outcomes

26 Jan 2017 by under Research/Treatment

640px DNA methylation 100x100 New drug could reduce DNA modifications, improve mesothelioma patient outcomes A new drug holds the potential to remove modifications often associated with cancer cells and  decrease treatment resistance to improve .

Mesothelioma Research News reports drug 5-aza-dC has been found in a recent study to reduce DNA methylation, a common gene “signaling tool that locks the genes in the ‘off’ position,” according to Nature Education, and could possibly “improve the effectiveness of anti-cancer drugs and reduce the most aggressive mesothelioma cells that are often associated with treatment resistance.” (more…)


Alimta developer to be inducted into Chemistry Hall of Fame

1 Jan 2010 by under News, People, Research/Treatment

edward taylor 100x100 Alimta developer to be inducted into Chemistry Hall of FamePrinceton University announced Edward Taylor, its A. Barton Hepburn Professor of Organic Chemistry Emeritus, will be inducted into the American Chemical Society (ACS) Division of Medicinal Chemistry Hall of Fame in 2010. Additionally, Taylor has been inducted into the New Jersey Inventors Hall of Fame and was selected to receive the 2010 Alfred Burger Award in Medicinal Chemistry from the ACS. Taylor was instrumental in the development of , a drug manufactured by Eli Lilly and Co. and approved for the treatment of malignant pleural by the U.S. Food & Drug Administration in 2004.

Taylor was recently honored for his accomplishments at the Celebrate Princeton Invention reception, held Dec. 18. He developed Alimta in partnership with scientists at Eli Lilly and Co.  after spending more than 40 years on the Princeton faculty. However, he began research that would lead to the mesothelioma drug’s development while a graduate student at Cornell University.

According to a Princeton news release, Taylor became fascinated by reports of a compound obtained from spinach and liver that had a unique chemical structure with a nucleus previously only observed in the pigments of butterfly wings. The compound from liver, now known as folic acid, he found was essential for the synthesis of DNA and RNA, and for the growth of cells.  Taylor observed that changes to the structure of folic acid could transform it from a growth-promoting to a growth-inhibiting compound, and dedicated his career to determine how it could be used to kill cancer cells.

Since its approval by the FDA in 2004, the drug has received three additional FDA approvals, most recently in July when it became the first chemotherapy approved for use as a maintenance therapy for patients with locally advanced or metastatic nonsquamous non-small cell lung cancer. Alimta has been successful in improving the quality of life and extending the lifespan of millions of cancer patients in nearly 100 countries around the world.

Taylor has previously been honored with the ACS Heroes of Chemistry Award, the International Society of Heterocyclic Chemistry Senior Award in Heterocyclic Chemistry, and the Research and Development Council of New Jersey’s Thomas Alva Edison Patent Award for Invention.